Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201306051 Principal Investigator: Tan, Benjamin
Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: III Disease Site: Liver
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to find out if cabozantinib is effective in treating liver cancer. This study will also examine how safe cabozantinib is and how well people with
liver cancer tolerate cabozantinib.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)